

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Sirtuin 1 (SIRT1); AMP-activated protein kinase (AMPK)	<i>In vitro</i> and mouse studies suggest activating SIRT1 or AMPK could help prevent hypoxia-induced chemotherapy resistance. In non-small cell lung cancer (NSCLC) cell lines, hypoxic conditions decreased AMPK activation, SIRT1 expression and response to the generic chemotherapeutics cisplatin or doxorubicin compared with normoxic conditions. In mice with NSCLC xenografts, a SIRT1 activator plus cisplatin decreased tumor volume more than cisplatin alone, but the effects of SIRT1 activation could be prevented by AMPK inhibition. Next steps could include testing in additional animal models of cancer.	Patent and licensing status unavailable	Shin, D.H. <i>et al. Cancer Res.</i> ; published online Nov. 15, 2013; doi:10.1158/0008-5472.CAN-13-2620 Contact: Jong-Wan Park, Seoul National University College of Medicine, Seoul, South Korea e-mail: parkjw@snu.ac.kr
<p>SciBX 7(1); doi:10.1038/scibx.2014.10 Published online Jan. 9, 2014</p>				